GSK Acquires US Cancer Biotech Nuvalent for $10.6 Billion

British pharmaceutical giant GSK has announced its largest-ever acquisition, agreeing to buy Boston-based biotech company Nuvalent for $10.6 billion (£8.0 billion) in a landmark deal that marks a major strategic bet by new Chief Executive Luke Miels. The acquisition, announced on Tuesday, brings GSK three promising lung cancer treatments and positions the company for rapid expansion in the oncology market.

The Deal

Under the terms of the agreement, GSK will pay $124 per share in cash — a 40% premium to Nuvalent’s last closing price. Net of cash acquired, GSK’s aggregate investment is estimated at $9.4 billion (£7.1 billion). The transaction, which has been more than a year in the making, is expected to close in the third quarter of 2026, subject to regulatory clearance and shareholder approval, according to a GSK press release.

Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company founded in 2017 by Harvard professor Matthew Shair, specializing in precisely targeted oncology therapies. The company went public on the Nasdaq in 2021. Its largest shareholder is Deerfield Management, a New York-based healthcare investment firm.

Three Lung Cancer Assets

The acquisition centers on three products targeting non-small cell lung cancer (NSCLC), the most common form of lung cancer, which primarily affects working-age adults aged 40 to 50, many of whom are non-smokers:

Zidesamtinib (NVL-520): A late-stage, next-generation ROS1 inhibitor currently under FDA review with a target decision date of September 18, 2026. It has received FDA Breakthrough Therapy and Orphan Drug Designations.
Neladalkib (NVL-655): A late-stage ALK inhibitor also under FDA review, with a target decision date of November 27, 2026. It likewise holds Breakthrough Therapy and Orphan Drug Designations.
NVL-330: A potential best-in-class HER2 inhibitor currently in Phase I trials for HER2-altered NSCLC.

The deal also includes Nuvalent’s preclinical portfolio of multiple programs.

Both lead assets have shown potential best-in-class profiles in clinical data presented at major oncology conferences, aiming for longer effective treatment with better quality of life through improved tolerability and enhanced blood-brain barrier penetration.

Strategic Rationale

This is the first major deal under Luke Miels, who became GSK CEO at the start of 2026 after replacing Emma Walmsley. The Guardian reported that Miels described Nuvalent’s scientists as an “impressive group of people” and said: “I really became convinced that this was a deal that we needed to do.”

Speaking about lung cancer patients, Miels noted: “These are relatively young people. They’ve got kids, they [lead] active lives … Clearly there’s a gap for a much-better-tolerated product.”

The acquisition accelerates GSK’s entry into lung cancer and provides a platform for expansion with Ris-Rez, GSK’s B7-H3 antibody-drug conjugate (ADC) currently in Phase III clinical development. It is consistent with GSK’s strategy of acquiring assets with validated targets that address efficacy and tolerability limitations of existing therapies.

Financial Impact

GSK said there is no change to its 2026 full-year guidance of 7–9% core operating profit and core EPS growth. The acquisition is expected to:

Contribute to revenue growth from 2027
Be accretive to core operating profit in 2027 and core EPS in 2029
Be incremental to GSK’s ambition for sales of more than £40 billion by 2031
Result in low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028

The company reaffirmed its 70p expected dividend for 2026 and progressive dividend policy. The transaction will be funded primarily from new and existing debt facilities plus cash, with no impact expected to GSK’s credit rating.

Market reaction was swift: Nuvalent shares soared 38% in pre-market trading to $122, while GSK shares fell 3% on the news.

Belgian Angle

While GSK is headquartered in London, the company has a significant presence in Belgium, with major operations in Rixensart (vaccine R&D) and Wavre. The story was first reported in Belgium by La Libre Belgique and RTBF, reflecting the local interest in GSK’s corporate strategy. The acquisition comes amid a period of restructuring for GSK’s Belgian operations, including recent layoffs at the Wavre site and the closure of the Gembloux research center in November 2025.

What’s Next

The tender offer for Nuvalent’s shares will commence within 10 business days. All eyes are now on the FDA’s upcoming decisions on zidesamtinib and neladalkib, which could allow GSK to launch potential blockbuster products as early as late 2026. The deal signals that Miels is prepared to pursue bold, large-scale acquisitions to drive GSK’s growth, raising questions about whether further major deals may follow.